LifeBond Secures $27 Million Investment to Market Sealant

Israel-based LifeBond announced that it has closed a $27M Series D preferred equity investment to market a surgical sealant.

The financing will support the company, a developer and manufacturer of medical devices for bio-surgery and tissue repair, in its introduction and commercialization of the LifeSeal surgical sealant in the European Union.

LifeSeal is the company’s flagship product, which is aimed at minimizing post-operative complications of bariatric and gastrointestinal procedures such as staple-line leakage by forming a reinforcement layer on a soft tissue site.

The investment will also support a comprehensive study as the company seeks FDA pre-market approval of the product. LifeBond plans to begin enrolling patients for the study in 2016. —Michael Cipriano